{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:04:24Z","timestamp":1786997064998,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.soncn.2019.150951","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T09:10:22Z","timestamp":1574241022000},"page":"150951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Adult Acute Lymphoblastic Leukemia: Treatment and Management Updates"],"prefix":"10.1016","volume":"35","author":[{"given":"Stephanie","family":"Gregory","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.soncn.2019.150951_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0703-z","article-title":"Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.soncn.2019.150951_bib0002","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"G\u00f6kbuget","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.soncn.2019.150951_bib0003","first-page":"166","article-title":"Treatment of relapsed\/refractory acute lymphoblastic leukemia","volume":"17","author":"Paul","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.soncn.2019.150951_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.soncn.2019.150951_bib0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ctrv.2018.04.002","article-title":"Bispecific antibodies in haematological malignancies","volume":"65","author":"Viardot","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.soncn.2019.150951_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-015-0195-4","article-title":"Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19\/CD3 for refractory acute lymphoid leukemia","volume":"8","author":"Wu","year":"2015","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.soncn.2019.150951_bib0007","first-page":"143","article-title":"Anti-CD19 monoclonal antibodies: a new approach to lymphoma therapy","volume":"4","author":"Naddafi","year":"2015","journal-title":"Int J Mol Cell Med"},{"key":"10.1016\/j.soncn.2019.150951_bib0008","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2019.150951_bib0009","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2019.150951_bib0010","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2019.150951_bib0011","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","article-title":"Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia","volume":"17","author":"Assi","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.soncn.2019.150951_bib0012","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1188\/17.CJON.S2.22-28","article-title":"CAR T-cell therapy: pediatric patients with relapsed and refractory acute lymphoblastic leukemia","volume":"21","author":"Callahan","year":"2017","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.soncn.2019.150951_bib0013","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2019.150951_bib0014","first-page":"6","article-title":"CAR T-cell therapy: update on the state of the science","volume":"23","author":"Lamprecht","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.soncn.2019.150951_bib0015","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2019.150951_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.soncn.2019.150951_bib0017","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.soncn.2019.150951_bib0018","series-title":"Package insert","year":"2017"},{"issue":"suppl 1","key":"10.1016\/j.soncn.2019.150951_bib0019","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1182\/blood-2018-99-111531","article-title":"Updated phase 1 results of ZUMA 3: KTE-C19, an anti-CD19 chimeric antigen receptor T cell therapy, in adult patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"132","author":"Wierda","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2019.150951_bib0020","first-page":"13","article-title":"Associated toxicities: assessment and management related to CAR T-cell therapy","volume":"23","author":"Anderson","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.soncn.2019.150951_bib0021","first-page":"216","article-title":"Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: Current treatments and future perspectives","volume":"16","author":"Yilmaz","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.soncn.2019.150951_bib0022","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2019.150951_bib0023","series-title":"Package insert","year":"2018"},{"key":"10.1016\/j.soncn.2019.150951_bib0024","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.beha.2017.09.002","article-title":"Cytokine release syndrome: who is at risk and how to treat","volume":"30","author":"Frey","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.soncn.2019.150951_bib0025","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S150524","article-title":"Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy","volume":"15","author":"Riegler","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.soncn.2019.150951_bib0026","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurological toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.soncn.2019.150951_bib0027","first-page":"1","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.soncn.2019.150951_bib0028","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). V5.0. 2018. Bethesda, MD; National Institutes of Health. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. (Accessed May 6, 2019)."},{"key":"10.1016\/j.soncn.2019.150951_bib0029","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T cell therapy \u2013 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.soncn.2019.150951_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1188\/17.CJON.S2.29-34","article-title":"Cytokine release syndrome: inpatient care for side effects of CAR T-cell therapy","volume":"21","author":"Smith","year":"2017","journal-title":"Clin J Oncol Nurs"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208119301330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208119301330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:35:57Z","timestamp":1760081757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208119301330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0749208119301330"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2019.150951","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adult Acute Lymphoblastic Leukemia: Treatment and Management Updates","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2019.150951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"150951"}}